Passage BIO, Inc. — Form 10-Q
Filed August 10, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
William Chou (CEO) and Kathleen Borthwick (CFO) signed Sarbanes-Oxley Section 302 and 906 certifications on August 10, 2026 for the Q2 2026 10-Q (period ended June 30, 2026). Both officers certified that the quarterly report contains no untrue material statements, that financial statements fairly present the company's condition and cash flows, and that internal controls over financial reporting are effective. No material weaknesses, deficiencies, or fraud in internal controls were disclosed.
Why this rating
Routine SOX certification; no operational, financial, or control-related changes disclosed. Standard quarterly compliance filing.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.